Analysis of inflammatory and anemia-related biomarkers in a randomized, double-blind, placebo-controlled study of siltuximab (anti-IL6 monoclonal antibody) in patients with multicentric castleman disease

Clinical Cancer Research

Volumn 21, Issue 19, 2015, Pages 4294-42304

  Casper, Corey ^a   Chaturvedi, Shalini ^b   Munshi, Nikhil ^c   Wong, Raymond ^d   Qi, Ming ^b   Schaffer, Michael ^b   Bandekar, Rajesh ^b   Hall, Brett ^b   Van De Velde, Helgi ^b   Vermeulen, Jessica ^e   Reddy, Manjula ^b   Van Rhee, Frits ^f  

^a Fred Hutchinson Cancer Research Center   (United States)

^b JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^c HARVARD MEDICAL SCHOOL   (United States)

^d CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^e Janssen Research and Development   (Netherlands)

^f UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; FERRITIN; HEMOGLOBIN; HEPCIDIN; INTERLEUKIN 6; PLACEBO; PREDNISONE; SILTUXIMAB; ANTINEOPLASTIC AGENT; IRON; MONOCLONAL ANTIBODY;

ADULT; ANEMIA; ANGIOFOLLICULAR LYMPH NODE HYPERPLASIA; ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG RESPONSE; ETHNICITY; FEMALE; HISTOPATHOLOGY; HUMAN; INFLAMMATION; IRON BINDING CAPACITY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYMPTOM; AGED; ANTAGONISTS AND INHIBITORS; BLOOD; CLINICAL TRIAL; GIANT LYMPH NODE HYPERPLASIA; MEAN CORPUSCULAR VOLUME; MIDDLE AGED; MULTICENTER STUDY; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BIOMARKERS; C-REACTIVE PROTEIN; ERYTHROCYTE INDICES; FEMALE; GIANT LYMPH NODE HYPERPLASIA; HEPCIDINS; HUMANS; INTERLEUKIN-6; IRON; MALE; MIDDLE AGED; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84945536472     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-15-0134     Document Type: Article

References (34)

1. Castleman B, Iverson L, Menendez VP. Localized mediastinal lymphnode hyperplasia resembling thymoma. Cancer 1956;9:822-30.
2. Waterston A, BowerM. Fifty years of multicentric Castleman's disease. Acta Oncol 2004;43:698-704.
3. Cronin DM, Warnke RA. Castleman disease: an update on classification and the spectrum of associated lesions. Adv Anat Pathol 2009;16:236-46.
4. Yoshizaki K,Matsuda T, Nishimoto N, Kuritani T, Taeho L, Aozasa K, et al. Pathogenic significance of interleukin-6 (IL-6/BSF-2) in Castleman's disease. Blood 1989;74:1360-7.
5. Casper C. The aetiology andmanagement of Castleman disease at 50 years: translating pathophysiology to patient care. Br J Haematol 2005;129:3-17.
6. Gérard L, Bérezné A, Galicier L, Meignin V, Obadia M, De Castro N, et al. Prospective study of rituximab in chemotherapy-dependent human immunodeficiency virus associated multicentric Castleman's disease: ANRS 117 CastlemaB Trial. J Clin Oncol 2007;25:3350-6.
7. Nishimoto N, Kanakura Y, Aozasa K, Johkoh T, Nakamura M, Nakano S, et al. Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease. Blood 2005;106:2627-32.
8. Venkiteshwaran A. Tocilizumab. MAbs 2009;1:432-8.
9. Hirano T, Matsuda T, Nakajima K. Signal transduction through gp130 that is shared among the receptors for the interleukin 6 related cytokine subfamily. Stem Cells 1994;12:262-77.
10. Kishimoto T. The biology of interleukin-6. Blood 1989;74:1-10.
11. Tanaka T, NarazakiM,Ogata A, Kishimoto T. A new era for the treatment of inflammatory autoimmune diseases by interleukin-6 blockade strategy. Semin Immunol 2014;26:88-96.
12. Kurzrock R, Voorhees PM, Casper C, Furman RR, Fayad L, Lonial S, et al. A phase I, open-label study of siltuximab, an anti-IL-6 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma, multiple myeloma, or Castleman disease. Clin Cancer Res 2013;19:3659-70.
13. Van Rhee F, Fayad L, Voorhees P, Furman R, Lonial S, Borghaei H, et al. Siltuximab, a novel anti-interleukin-6 monoclonal antibody, for Castleman's disease. J Clin Oncol 2010;28:3701-8.
14. Van Rhee F, Wong RS, Munshi N, Rossi JF, Ke XY, Fossa A, et al. Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial. Lancet Oncol 2014;15:966-74.
15. European Commission [Internet]. Community register of medicinal products for human use: SYLVANT authorisation. [updated 2014; cited 2014 Jun 3]. Available from: http://ec.europa.eu/health/documents/community-register/html/h928.htm.
16. US Food and Drug Administration [Internet]. FDA approves Sylvant for rare Castleman's disease. [updated 2014; cited 2014 Jun 3]. Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/UCM394522.htm
17. Dispenzieri A, Armitage JO, Loe MJ,Geyer SM, Allred J, Camoriano JK, et al. The clinical spectrum of Castleman's disease. Am J Hematol 2012;87: 997-1002.
18. Castell JV, Gomez-Lechon MJ, David M, Fabra R, Trullenque R, Heinrich PC. Acute-phase response of human hepatocytes: regulation of acutephase protein synthesis by interleukin-6. Hepatology 1990;12: 1179-86.
19. Puchalski T, Prabhakar U, Jiao Q, Berns B, Davis HM. Pharmacokinetic and pharmacodynamic modeling of an anti-interleukin-6 chimeric monoclonal antibody (siltuximab) in patients with metastatic renal cell carcinoma. Clin Cancer Res 2010;16:1652-61.
20. Mahmoud FA, Rivera NI. The role of C-reactive protein as a prognostic indicator in advanced cancer. Curr Oncol Rep 2002;4:250-5.
21. Pelliniemi TT, Irjala K, Mattila K, Pulkki K, Rajamaki A, Tienhaara A, et al. Immunoreactive interleukin-6 and acute phase proteins as prognostic factors in multiple myeloma. Finnish Leukemia Group. Blood 1995;85: 765-71.
22. Ljungberg B, Grankvist K, Rasmuson T. Serum interleukin-6 in relation to acute-phase reactants and survival in patientswith renal cell carcinoma. Eur J Cancer 1997;33:1794-8.
23. Ganz T, Olbina G, Girelli D, Nemeth E, Westerman M. Immunoassay for human serum hepcidin. Blood 2008;112:4292-7.
24. Cucuianu A, Patiu M, Rusu A. Hepcidin and multiple myeloma related anemia. Med Hypotheses 2006;66:352-4.
25. Zaritsky J, Young B, Wang HJ, Westerman M, Olbina G, Nemeth E, et al. Hepcidin-a potential novel biomarker for iron status in chronic kidney disease. Clin J Am Soc Nephrol 2009;4:1051-6.
26. Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999;17:1244.
27. Wu TL, Tsao KC, Chang CP, Li CN, Sun CF, Wu JT. Development of ELISA on microplate for serum C-reactive protein and establishment of agedependent normal reference range. Clin Chim Acta 2002;322:163-8.
28. Pepys MB, HirschfieldGM.C-reactive protein: a critical update. JClin Invest 2003;111:1805-12.
29. Mast AE, Schlumpf KS, Wright DJ, Johnson B, Glynn SA, Busch MP, et al. Hepcidin level predicts hemoglobin concentration in individuals undergoing repeated phlebotomy. Haematologica 2013;98: 1324-30.
30. Agrawal A, Cha-Molstad H, Samols D, Kushner I. Overexpressed nuclear factor-kappaB can participate in endogenous C-reactive protein induction, and enhances the effects of C/EBPbeta and signal transducer and activator of transcription-3. Immunology 2003;108: 539-47.
31. Stone K, Woods E, Szmania SM, Stephens OW, Garg TK, Barlogie B, et al. Interleukin-6 receptor polymorphism is prevalent in HIV-negative Castleman Disease and is associated with increased soluble interleukin-6 receptor levels. PLoS One 2013;8:e54610.
32. Nemeth E, Rivera S, Gabayan V, Keller C, Taudorf S, Pedersen BK, et al. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest 2004;113:1271-6.
33. Nicolas G, Chauvet C, Viatte L, Danan JL, Bigard X, Devaux I, et al. The gene encoding the iron regulatory peptide hepcidin is regulated by anemia, hypoxia, and inflammation. J Clin Invest 2002;110:1037-44.
34. Andriopoulos B Jr., Corradini E, Xia Y, Faasse SA, Chen S, Grgurevic L, et al. BMP6 is a key endogenous regulator of hepcidin expression and iron metabolism. Nat Genet 2009;41:482-7.